Cancer

Abstract Background Index lesion‐focused ipsilateral systematic biopsy (iSB) has been proposed as a core‐reduction alternative to MRI‐targeted biopsy combined with systematic biopsy (TB + SB) for prostate cancer, but prospective multicenter validation is limited. Methods This prospective multicenter trial (NCT06584279) enrolled biopsy‐naive men with Prostate Imaging Reporting and Data System (PI‐…

Abstract Background Therapeutic strategies for myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs) remain suboptimal. Selinexor, an oral selective inhibitor of exportin 1, represents a mechanism‐based therapeutic approach. Preclinical and clinical evidence indicated synergistic antileukemic effects when selinexor was combined with hypomethylating agents or janus kinase inhibitors. Me…

Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported. Methods Patients were randomized 1:1 to olaparib plus radium‐22…

Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment-naive patients. Further investigation is warranted.

Poverty in the surrounding counties has a greater impact on mortality among survivors than residential county poverty alone. Incorporating poverty levels from both residential and surrounding counties can improve definitions of high- and low-risk regions after a breast cancer diagnosis.

Clinicaltrials.gov (NCT03297034).

IDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision-making in CS patients.

Guideline‐concordant care in triple‐negative breast cancer was associated with improved survival, including from nonbreast cancer causes. This editorial explores what broader patient and health system influences, beyond treatment, are captured by guideline concordance.

Larger baseline tumor burden was associated with worse OS, but not PFS, and was not predictive of tumor regression after dual ICI therapy in a large cohort with rare cancer types.

WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA-targeting agents for r/r MM treatment.

For most types of cancer, psychosocial factors (measured at a single point in time) were not associated with increased risk. PSS, currently not in a relationship, and loss were associated with an increased risk of lung cancer, although most effects attenuated when adjusting for several known risk factors.

The CMOP regimen demonstrates a favorable PK profile, a manageable safety profile, and encouraging preliminary antitumor activity.

In the IMAGE (Integrative Molecular And Genetic Epidemiology study) data set, men with newly diagnosed multiple myeloma had a higher burden of disease, more end‐organ damage, and were less likely to have light chain–only disease and osteopenia than women. Interactions between sex and age regarding a free light chain ratio ≥100 and copy number alterations suggest a potential role for sex hormones …

The trial registration is ClinicalTrials.gov NCT04773639.

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, according to results of the phase 3 MajesTEC‐3 trial, the combination of teclistamab plus daratumumab in patients with early relapsed myeloma significantly improved progression‐free survival and led to an overall survival advantage in comparison with the standard of car…

Gnathic osteosarcoma may vary from appendicular osteosarcoma in terms of the general systemic therapy approach. Consensus guidelines highlighting literature‐based recommendations allow for care recommendations and set a research direction as the field starts to approach methods to reveal osteosarcoma subtypes and improve outcomes.